Goldman Sachs’s Nanobiotix NBTX Stock Holding History

Goldman Sachs’s Portfolio NBTX Stock Details NBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,498	Closed	-$30.1K	–	6303
2024 Q4	$30.1K	Buy	+10,498	New	+$42K	﹤0.01%	5871

Other funds holding NBTX

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Goldman Sachs's NBTX Position: Q1 2025 in Review

Goldman Sachs sold out of Nanobiotix (NBTX) in Q1 2025, closing a stake of 10,498 shares — an estimated $30.1K sold.

Goldman Sachs first reported a position in NBTX in Q4 2024 and held it in 1 quarter. The position peaked at $30.1K in Q4 2024. 12 funds tracked by Wall St. Rank hold NBTX as of Q1 2025.

Goldman Sachs reported no remaining Nanobiotix position as of Q1 2025 after selling out during the quarter.
Goldman Sachs sold 10,498 Nanobiotix shares in Q1 2025, an estimated $30.1K.
Goldman Sachs first reported a position in Nanobiotix in Q4 2024 and held it in 1 quarter.
Goldman Sachs's Nanobiotix position peaked at $30.1K in Q4 2024.
12 funds tracked by Wall St. Rank held Nanobiotix as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.